by Sucralfate is widely used as an antiulcer and antacid medication for the treatment of peptic ulcer disease and gastroesophageal reflux disease (GERD). It acts by forming a coating barrier over ulcers to protect them against further digestion by gastric acid and pepsin. Sucralfate is available in oral formulations such as tablets and suspensions to provide symptomatic relief from ulcers. The demand for sucralfate drugs is growing in the U.S. owing to the rising prevalence of digestive disorders like gastric and duodenal ulcers.
The global Sucralfate market is estimated to be valued at US$ 60.8 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Artificial intelligence (AI) holds promising growth opportunities for the sucralfate market growth. Several startups are developing AI-powered drugs and technologies for gastrointestinal diseases. For instance, Anthropic is an AI safety startup developing AI assistants to detect digestive issues and recommend treatment options. Their AI model analyses patterns in patients’ symptoms, medical histories, medications, and lab test results to determine the root cause of problems and suggest the safest treatment paths. This brings convenience and accessibility of gastrointestinal care. AI can potentially reduce dependence on sucralfate drugs by preventing recurrence of ulcers through early detection and personalized therapy recommendations. While sucralfate remains the standard care, AI-based screening and management offer an attractive value-added approach that is likely to gain adoption in the coming years.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the U.S. sucralfate market is moderate. Factors such as capital requirement and established brand loyalty pose as a deterrent for new players.
Bargaining power of buyers: The bargaining power of buyers in the U.S. sucralfate market is high. The availability of generic drugs exert pressure on prices.
Bargaining power of suppliers: The bargaining power of suppliers is moderate. The key raw material suppliers hold a critical position, however established manufacturers have a diversified supplier base to mitigate sole sourcing risks.
Threat of new substitutes: The threat of substitutes is moderate. Other drugs prescribed for the same indications pose as substitutes.
Competitive rivalry: The competition in the U.S. sucralfate market is high owing to the presence of numerous international and regional players.
Key Takeaways
The global U.S. sucralfate market is expected to witness high growth. The market size for 2024 is US$ 60.8 Mn and is projected to grow at a CAGR of 5.6% during the forecast period of 2023 to 2030.
Regional analysis: The North Central region dominates the U.S. sucralfate market accounting for over 35% of the market share owing to higher prevalence of gastric ulcers. The Western region is expected grow at the fastest pace over the forecast period.
Key players: Key players operating in the U.S. sucralfate market are Biotechnica Pharma Global, Marlwood Therapeutics Inc., Pfizer Inc., McKinley Resources, Gelnex, Saviour Lifetec Corporation, and Reyoung Pharmaceutical Co. Ltd.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
